As the Executive Director and Global & US Medical Affairs Lead for Oncology at Eli Lilly and Company, Katheryn Md plays a pivotal role in shaping the strategic direction of medical affairs within the oncology therapeutic area. With a robust clinical background, she leverages her...
As the Executive Director and Global & US Medical Affairs Lead for Oncology at Eli Lilly and Company, Katheryn Md plays a pivotal role in shaping the strategic direction of medical affairs within the oncology therapeutic area. With a robust clinical background, she leverages her expertise to inform critical medical and business decisions that directly enhance patient care and outcomes. Katheryn is particularly focused on ensuring patient access to innovative therapies, exemplified by her leadership in establishing a comprehensive medical affairs plan for a breast cancer indication within a major brand. This initiative not only underscores her commitment to patient-centric strategies but also highlights her ability to navigate complex regulatory landscapes and lifecycle management processes.
In her current role, Katheryn fosters cross-functional collaborations, driving a culture of respect and accountability across teams. Her strategic vision aligns seamlessly with Eli Lilly’s organizational mission, enabling her to advocate for policies and procedures that enhance the customer experience. Katheryn's expertise in integrated planning and healthcare consulting allows her to effectively communicate complex medical data, ensuring that stakeholders are well-informed and aligned with the company’s goals. Additionally, her proficiency in data visualization and electronic health records (EHR) enhances her ability to translate clinical insights into actionable strategies that support product positioning and market access.
Through her leadership, Katheryn Md not only champions innovative oncology solutions but also exemplifies the importance of a collaborative approach in the medical affairs landscape. Her commitment to advancing patient care, combined with her strategic acumen, positions her as a key influencer in the oncology field, driving initiatives that ultimately improve patient experiences and health outcomes.
